Vyant Bio, Inc.
VYNT
OTC PK
| 06/30/2023 | 03/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 48.75% | 73.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 48.75% | 73.91% | |||
| Cost of Revenue | 94.37% | 132.79% | |||
| Gross Profit | -153.23% | -313.33% | |||
| SG&A Expenses | -50.00% | 26.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -60.14% | 12.48% | |||
| Operating Income | 62.12% | -11.77% | |||
| Income Before Tax | 62.45% | -26.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 62.45% | -26.22% | |||
| Earnings from Discontinued Operations | -- | 81.69% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 63.73% | -5.19% | |||
| EBIT | 62.12% | -11.77% | |||
| EBITDA | 61.93% | -12.30% | |||
| EPS Basic | 64.18% | 0.60% | |||
| Normalized Basic EPS | 62.92% | -5.79% | |||
| EPS Diluted | 64.18% | 0.60% | |||
| Normalized Diluted EPS | 62.92% | -5.79% | |||
| Average Basic Shares Outstanding | 1.27% | 5.82% | |||
| Average Diluted Shares Outstanding | 1.27% | 5.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||